Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

JAMA NetworkAssessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Publication: JAMA Oncology
Design: An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.
Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form